诺雷德（ICI 118,630）对前列腺癌患者垂体-性腺轴的长期有效抑制作用
Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).
作者信息
Murphy G P, Greco J, Huben R
机构信息
Department of Urology, State University of New York, Millard Fillmore Hospital, Buffalo.
出版信息
Urology. 1987 Nov;30(5):482-3. doi: 10.1016/0090-4295(87)90387-6.
PMID:2960064
Abstract
Eleven patients with prostatic cancer maintained on monthly depot Zoladex (ICI 118,630) from 20 to 23.5 months are described. All are in clinical remission. Castrate levels of testosterone are maintained, and low levels of LH and FSH were observed. Contrary to a prior report, persistent blockage of the pituitary-gonadal axis is achieved and maintained with no detectable adverse side effects.
摘要
本文描述了11例前列腺癌患者，他们每月接受一次长效诺雷德（ICI 118,630）治疗，持续时间为20至23.5个月。所有患者均处于临床缓解状态。睾酮维持在去势水平，促黄体生成素（LH）和促卵泡生成素（FSH）水平较低。与先前的一份报告相反，垂体-性腺轴实现并维持了持续阻断，且未发现可检测到的不良副作用。
相似文献
1
Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).诺雷德（ICI 118,630）对前列腺癌患者垂体-性腺轴的长期有效抑制作用
Urology. 1987 Nov;30(5):482-3. doi: 10.1016/0090-4295(87)90387-6.
2
Effects of the gonadotrophin-releasing hormone agonist 'Zoladex' upon pituitary and gonadal function in hypogonadal (hpg) male mice: a comparison with normal male and testicular feminized (tfm) mice.促性腺激素释放激素激动剂“诺雷德”对性腺功能减退（hpg）雄性小鼠垂体和性腺功能的影响：与正常雄性和睾丸雌性化（tfm）小鼠的比较。
J Mol Endocrinol. 1992 Jun;8(3):249-58. doi: 10.1677/jme.0.0080249.
3
Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.长期接受长效促黄体生成素释放激素（LHRH）类似物治疗的患者的催乳素和垂体促性腺激素值以及对急性LHRH激发试验的反应。
Cancer. 1991 Feb 1;67(3):557-9. doi: 10.1002/1097-0142(19910201)67:3<557::aid-cncr2820670304>3.0.co;2-c.
4
LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.促黄体生成素释放激素激动剂，诺雷德（戈舍瑞林）长效剂型治疗前列腺癌。日本随机剂量探索试验。
Am J Clin Oncol. 1988;11 Suppl 2:S108-11. doi: 10.1097/00000421-198801102-00026.
5
6
Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.促黄体生成素释放激素类似物ICI 118630（诺雷德）长效制剂用于前列腺癌患者的初步报告。
Br Med J (Clin Res Ed). 1985 Jan 19;290(6463):185-7. doi: 10.1136/bmj.290.6463.185.
7
Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.诺雷德：一种用于治疗晚期前列腺癌的长效、每月一次的促黄体生成素释放激素类似物。
J Clin Oncol. 1987 Jun;5(6):912-7. doi: 10.1200/JCO.1987.5.6.912.
8
The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.用缓释促黄体生成素释放激素类似物（Zoladex ICI 118630）治疗转移性前列腺癌。
Br J Urol. 1987 May;59(5):436-42. doi: 10.1111/j.1464-410x.1987.tb04842.x.
9
Prolonged suppression of rat testis function by a depot formulation of Zoladex, a GnRH agonist.戈舍瑞林（一种促性腺激素释放激素激动剂）长效注射制剂对大鼠睾丸功能的长期抑制作用
J Androl. 1989 Nov-Dec;10(6):478-86. doi: 10.1002/j.1939-4640.1989.tb00144.x.
10
Influence of continuous luteinizing hormone-releasing hormone agonist treatment on steroidogenic enzymes in the human testis.持续促黄体生成素释放激素激动剂治疗对人睾丸中类固醇生成酶的影响。
Scand J Urol Nephrol. 1987;21(4):267-71. doi: 10.3109/00365598709180780.
Zotero 插件